A new Editorial published in Translational Exercise Biomedicine (ISSN: 2942-6812), an official partner journal of International Federation of Sports Medicine (FIMS), argues that physical inactivity can no longer be described merely as a public-health crisis. Instead, the authors contend, it represents a persistent implementation failure of modern societies to align with fundamental human biology with consequences that strain global health systems, economic sustainability, and long-term human resilience. The editorial was authored by Yannis P. Pitsiladis, Daria Obratov, Fabio Pigozzi and Ugur Erdener.

Sight-threatening antibiotic-resistant eye infections are becoming a significant threat to vision in dogs, cats, and horses, according to a newly published comprehensive review. The study examines global trends in antimicrobial resistance in animal eye infections and warns that multidrug-resistant bacteria are becoming more common in referral veterinary settings. The review also highlights a critical challenge for veterinarians: standard laboratory tests may not always predict how well topical eye treatments will work in practice. The authors call for earlier diagnostic testing, more targeted antibiotic use, stronger infection-control measures, and the development of antibiotic-sparing strategies to help preserve treatment options for future patients.

A joint research team from China Pharmaceutical University, Chinese Academy of Agricultural Sciences, National Engineering Research Center for the Emergency Drug, and Shandong Agricultural University has developed a novel multisite bridging‑mediated lateral flow immunoassay (mbLFIA) that enables ultrasensitive, enzyme‑free, visual on‑site detection of mosquito‑borne viruses such as chikungunya virus (CHIKV). The breakthrough, published in Targetome, addresses a critical global need for field‑deployable diagnostics in resource‑limited regions, where conventional nucleic acid tests rely on bioenzymes and bulky laboratory instruments.

A novel natural compound crocin II from saffron directly targets ANGPTL8, a key driver of metabolic dysfunction‑associated steatotic liver disease (MASLD), and promotes its degradation via the autophagosome‑lysosome pathway. This PROTAC‑like mechanism suppresses lipogenesis, restores lipid metabolism, reverses hepatic steatosis, insulin resistance, and hyperlipidemia in preclinical models, with excellent organ safety, providing a safe, translatable natural strategy for MASLD therapy.

A new study reveals cathepsin S (CTSS) as a key immune checkpoint driving cholestatic liver injury by skewing invariant natural killer T (iNKT) cells toward pathogenic iNKT17 polarization. The natural product celastrol directly binds and inhibits CTSS, restores autophagy/mitophagy in iNKT cells, reprograms the liver immune microenvironment toward protective iNKT1 polarization, alleviates cholestasis, and halts liver fibrosis, establishing a safe, translatable immune‑targeting strategy for cholestatic liver diseases.